Solid Bioscience
The $12B Alarm Bell: Smart Money is Buying Solid Biosciences ($SLDB) While Retail Investors are Sleeping
Novartis's $12B acquisition of Avidity just repriced the gene therapy market, yet Solid Biosciences lags far behind. Top institutional investors see de-risked biology and standout safety in SLDB's early data. Are retail investors missing one of the most asymmetric opportunity in biotech?